Mizagliflozin

AssetAlso called VGX-001-013, EMERGE, DSP-3235, KGA-3235

Inhibits intestinal SGLT1 to reduce glucose absorption and blunt postprandial glucose excursions.

Stage
Phase 2
Modality
Small molecule
Target
Not known
1
Indication
2
Trials
1
Developer

Trial NCT07760961 is still running. Mizagliflozin: data expected on Nov 6, 2026. SEC filing

Indications

1

In the full profile

  • Owner and partners1
  • Trials2
  • Evidence for its targets1
  • Signals4

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets